A randomized phase iii study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 6, 2010, Pages 1009-1021

  Bamias, Aristotelis ^a   Karina, M ^b   Papakostas, P ^c   Kostopoulos, I ^b   Bobos, M ^b   Vourli, G ^d   Samantas, E ^e   Christodoulou, Ch ^f   Pentheroudakis, G ^g   Pectasides, D ^h   Dimopoulos, M A ^a   Fountzilas, G ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c HIPPOKRATION HOSPITAL   (Greece)

^d Hellenic Cooperative Oncology Group   (Greece)

^e AGII ANARGIRI CANCER HOSPITAL   (Greece)

^f METROPOLITAN HOSPITAL   (Greece)

^g UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^h NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM COMPLEX; SCATTER FACTOR RECEPTOR; TAU PROTEIN; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTRECTOMY; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TISSUE MICROARRAY; VOMITING; ADJUVANT CHEMOTHERAPY; CHEMICALLY INDUCED DISORDER; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; STOMACH TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DIARRHEA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TAXOIDS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77951885560     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1256-6     Document Type: Article

References (52)

1. Van Cutsem E, Dicato M, Arber N, Benson A, Cunningham D, Diaz-Rubio E, Glimelius B, Goldberg R, Haller D, Haustermans K, Koo-Kang Y, Labianca R, Lang I, Minsky B, Nordlinger B, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Szawlowski A, van de Velde C (2006) The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. Ann Oncol 17 (Suppl 6):vi13-vi18. doi:10.1093/annonc/mdl976
2. Ferlay J, Bray F, Pisani P, Parkin DM (2001) Cancer incidence, mortality and prevalence worldwide, version 1.0. Lyon IARC Press, IARC Cancer Base No. 5
3. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E (2005) Gastric cancer. Crit Rev Oncol Hematol 54:209-241. doi:10.1016/j. critrevonc.2005.01.002 (Pubitemid 40703920)
4. Ajani JA (2005) Evolving chemotherapy for advanced gastric cancer. Oncologist 10(Suppl 3):49-58
5. Macdonald JS (2004) Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 54(Suppl 1):S4-S11. doi:10.1007/s00280-004-0880-4 (Pubitemid 39517742)
6. Sastre J, Garcia-Saenz JA, Diaz-Rubio E (2006) Chemotherapy for gastric cancer. World J Gastroenterol 12:204-213
7. Cunningham D, Jost LM, Purkalne G, Oliveira J (2005) ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. Ann Oncol. 16(Suppl 1):i22-i23. doi:10.1093/annonc/mdi812 (Pubitemid 40872975)
8. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730
9. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ MAGIC, Participants Trial (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
10. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, Group ACTS-GC (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral Xuoropyrimidine. N Engl J Med 357:1810-1820
11. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, Le Bail N, Verweij J (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70:380-383
12. Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dorken B, Reichardt P (2005) Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 23:494-501. doi:10.1200/JCO.2005.02.163 (Pubitemid 46237444)
13. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A, Swiss Group for Clinical Cancer Research (SAKK), The European Institute of Oncology (EIO) (2000) Docetaxel (Taxotere)-cisplatin (TC) : an effective drug combination in gastric carcinoma. Ann Oncol 11:301-306
14. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, Eichelmann K, Lippert H (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12:47-51
15. Smith I, Procter M, Gelber RD et al (2007) 2-year follow up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29-36
16. Dowsett M, Dunbier AK (2004) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14(24):8019-8026
17. de Castro-Carpeño J, Belda-Iniesta C, Casado Sáenz E, Hernández Agudo E, Feliu Batlle J, González Barón M (2008) EGFR and colon cancer: a clinical view. Clin Transl Oncol 10(1):6-13
18. Scartozzi M, Galizia E, Freddari F et al (2004) Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 30:451-459
19. Greene F, Page D, Fleming ID, et al. (2002) Stomach. In: AJCC cancer staging manual. New York: Springer-Verlaag, pp 99
20. Williams JH, Mepham BL, Wright DH (1997) Tissue preparation for immunocytochemistry. J Clin Pathol 50:422-428
21. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H (1999) The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85(9):1894-1902
22. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ (2007) Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18(3):504-509
23. Mimori K, Sadanaga N, Yoshikawa Y, Ishikawa K, Hashimoto M, Tanaka F, Sasaki A, Inoue H, Sugimachi K, Mori M (2006) Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment. Br J Cancer 94(12):1894-1897
24. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S (2005) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22:4772-4778
25. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL et al (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155(4):1253-1260
26. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072
27. Skarlos DV, Bai M, Goussia A, Samantas E, Galani E, Tsavdaridis D, Karina M, Papakostas P, Konstantara A, Fountzilas G (2007) Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group. Anticancer Res 27(4C):2973-2983
28. Tanaka S, Nohara T, Iwamoto M et al (2009) Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol 64:341-346
29. Huang ZH, Hua D, Du X et al (2008) ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastrenterol 14:6401-6407
30. Bellmunt J, Paz-Ares L, Cuello M et al (2007) Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18:522-528
31. Kopp R, Ruge M, Rothbauer E et al (2002) Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res 22:1161-1167
32. Garcia I, Vizoso F, Martin A et al (2003) Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10:234-241 (Pubitemid 40486955)
33. Lim EH, Zhang SL, Li ZL et al (2009) Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and cMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thor Oncol 4:12-21.
34. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ (2007) Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18(3):504-509
35. Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R, Liu B (2008) ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 98(8):1398-1402 Epub 2008 Mar. 25
36. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K (2008) Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 98(4):832-839 Epub 2008 Jan 29
37. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279
38. Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24:331-344
39. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC IALT, Investigators Bio (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983-991
40. Nogales E, Wolf SG, Downing KH (1998) Structure of the alpha beta tubulin dimer by electron crystallography. Nature 391(6663):199-203.
41. Erratum in: Nature 1998 May 14;393(6681):191
42. Drechsel DN, Hyman AA, Cobb MH, Kirschner MW (1992) Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 3:1141-1154
43. Nogales E, Wolf SG, Khan IA, Ludueña RF, Downing KH (1995) Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 375(6530):424-427
44. Yvon AC, Wadsworth P, Jordan MA (1999) Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10:947-959
45. Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L (2005) Microtubule associated protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 4(9):1149-1152
46. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L (2005) Microtubuleassociated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315-8320
47. Rosell R, Felip E (2001) Predicting response to paclitaxel/carboplatin- based therapy in non-small cell lung cancer. Semin Oncol 28(4 Suppl 14):37-44 (Pubitemid 32953991)
48. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A (2002) Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 98(6):833-837
49. Jain S, Filipe MI, Gullick WJ, Linehan J, Moris RW (1991) c-erbB-2 protooncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archive material. Int J Cancer 48:668-671
50. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, et al. (2009) Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27(18S):LBA4509
51. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S et al (1991) Evaluation of immunoreactivity for erbB2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 51:1034-1038
52. Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y (1993) Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 72:2083-2088